Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled DZIF-10c in SARS-CoV-2 Infection
NCT04631705Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lomtegovimab in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by University of Cologne. Primary endpoint: Proportion of Patients With Any Adverse Event at 7 days. Started Dec 2020; status: terminated.
02
Drugs
lomtegovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04631705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631705.